Skip to content

Study · Observational study · 2026

16 results

Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.

Chen SC, Liu KW, Huang YN, Meyerowitz-Katz G, Su PH

American journal of therapeutics17 Apr 2026

PMID41992281 (opens in a new tab)PMCIDPMC13549456 (opens in a new tab)DOI10.1097/mjt.0000000000002132 (opens in a new tab)PepBankPUB-41992281
Read at sourcePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide users had lower total cholesterol than naltrexone-bupropion users across follow-up.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to lower total cholesterol than naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with each comparator, semaglutide users had lower total cholesterol and LDL-C across follow-up; triglycerides were lower versus naltrexone-bupropion.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide users had lower total cholesterol than phentermine-topiramate users across follow-up.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to lower total cholesterol than phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal cholesterol vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with each comparator, semaglutide users had lower total cholesterol and LDL-C across follow-up; triglycerides were lower versus naltrexone-bupropion.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide users had lower LDL-C than naltrexone-bupropion users across follow-up.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to lower LDL cholesterol than naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL-C vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with each comparator, semaglutide users had lower total cholesterol and LDL-C across follow-up; triglycerides were lower versus naltrexone-bupropion.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide users had lower LDL-C than phentermine-topiramate users across follow-up.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to lower LDL cholesterol than phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL-C vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with each comparator, semaglutide users had lower total cholesterol and LDL-C across follow-up; triglycerides were lower versus naltrexone-bupropion.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  5. 05HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide users had lower triglycerides than naltrexone-bupropion users.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to lower triglycerides than naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglycerides vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with each comparator, semaglutide users had lower total cholesterol and LDL-C across follow-up; triglycerides were lower versus naltrexone-bupropion.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, HDL-C at 12-24 months was higher with phentermine-topiramate than with semaglutide.

    In plain wordsIn adults with obesity and no diabetes, HDL cholesterol was higher with phentermine-topiramate than with semaglutide at 12 to 24 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHDL-C vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HDL-C was higher with phentermine-topiramate at 12-24 months.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, HbA1c was lower with semaglutide than with naltrexone-bupropion at 12 and 24 months.

    In plain wordsIn adults with obesity and no diabetes, HbA1c was lower with semaglutide than with naltrexone-bupropion at 12 and 24 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HbA1c was lower with semaglutide versus naltrexone-bupropion at 12 and 24 months
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  8. 08HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, HbA1c was slightly higher with semaglutide than with phentermine-topiramate.

    In plain wordsIn adults with obesity and no diabetes, HbA1c was slightly higher with semaglutide than with phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    IncreaseHbA1c vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    slightly higher versus phentermine-topiramate.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  9. 09HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, between-group differences in creatinine were limited for semaglutide versus the two comparators.

    In plain wordsIn adults with obesity and no diabetes, creatinine differed little between semaglutide and the two comparison drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeCreatinine
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion or phentermine-topiramate
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Between-group differences in creatinine and estimated glomerular filtration rate were limited.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  10. 10HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, between-group differences in estimated glomerular filtration rate were limited for semaglutide versus the two comparators.

    In plain wordsIn adults with obesity and no diabetes, kidney filtration rate differed little between semaglutide and the two comparison drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeEstimated glomerular filtration rate
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion or phentermine-topiramate
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Between-group differences in creatinine and estimated glomerular filtration rate were limited.
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  11. 11HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide use was associated with a lower hazard of mortality than naltrexone-bupropion.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to fewer deaths than naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.51 HR
    vs naltrexone-bupropion
    Absolute risk difference
    −0.4%
    vs naltrexone-bupropion, 24 months

    Source sentences

    Summary
    Semaglutide use was associated with lower hazards of mortality (vs. naltrexone-bupropion: HR 0.51; ARD -0.4%; vs. phentermine-topiramate: HR 0.62; ARD -0.2%) and MAKE (vs. naltrexone-bupropion: HR 0.47; ARD -0.5%; vs. phentermine-topiramate: HR 0.48; ARD -0.4%).
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  12. 12HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide use was associated with a lower hazard of mortality than phentermine-topiramate.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to fewer deaths than phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause mortality vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.62 HR
    vs phentermine-topiramate
    Absolute risk difference
    −0.2%
    vs phentermine-topiramate, 24 months

    Source sentences

    Summary
    Semaglutide use was associated with lower hazards of mortality (vs. naltrexone-bupropion: HR 0.51; ARD -0.4%; vs. phentermine-topiramate: HR 0.62; ARD -0.2%) and MAKE (vs. naltrexone-bupropion: HR 0.47; ARD -0.5%; vs. phentermine-topiramate: HR 0.48; ARD -0.4%).
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  13. 13HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide use was associated with a lower hazard of major adverse kidney events than naltrexone-bupropion.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to fewer major kidney events than naltrexone-bupropion.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse kidney events vs naltrexone-bupropion
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.47 HR
    vs naltrexone-bupropion
    Absolute risk difference
    −0.5%
    vs naltrexone-bupropion, 24 months

    Source sentences

    Summary
    Semaglutide use was associated with lower hazards of mortality (vs. naltrexone-bupropion: HR 0.51; ARD -0.4%; vs. phentermine-topiramate: HR 0.62; ARD -0.2%) and MAKE (vs. naltrexone-bupropion: HR 0.47; ARD -0.5%; vs. phentermine-topiramate: HR 0.48; ARD -0.4%).
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  14. 14HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, semaglutide use was associated with a lower hazard of major adverse kidney events than phentermine-topiramate.

    In plain wordsIn adults with obesity and no diabetes, semaglutide use was linked to fewer major kidney events than phentermine-topiramate.

    Peptide
    Semaglutide
    Outcome
    DecreaseMajor adverse kidney events vs phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    Phentermine-topiramate
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.48 HR
    vs phentermine-topiramate
    Absolute risk difference
    −0.4%
    vs phentermine-topiramate, 24 months

    Source sentences

    Summary
    Semaglutide use was associated with lower hazards of mortality (vs. naltrexone-bupropion: HR 0.51; ARD -0.4%; vs. phentermine-topiramate: HR 0.62; ARD -0.2%) and MAKE (vs. naltrexone-bupropion: HR 0.47; ARD -0.5%; vs. phentermine-topiramate: HR 0.48; ARD -0.4%).
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  15. 15HumanObservational studyEfficacy outcome

    In adults with obesity and no diabetes, major adverse liver outcome estimates for semaglutide versus the two comparators were near the null.

    In plain wordsIn adults with obesity and no diabetes, major liver events did not clearly differ between semaglutide and the two comparison drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeMajor adverse liver outcomes
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion or phentermine-topiramate
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Major adverse liver outcome and pancreatitis estimates were near the null
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.
  16. 16HumanObservational studySafety outcome

    In adults with obesity and no diabetes, pancreatitis estimates for semaglutide versus the two comparators were near the null.

    In plain wordsIn adults with obesity and no diabetes, pancreatitis did not clearly differ between semaglutide and the two comparison drugs.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute pancreatitis
    Study

    n: not reported in source

    Comparator
    Naltrexone-bupropion or phentermine-topiramate
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and pancreatitis estimates were near the null
    2 context sentences
    Summary · context
    Retrospective cohort study in the TriNetX US Collaborative Network (2021-2025).
    Summary · context
    New users were propensity-score matched 1:1 and followed for up to 24 months in an intention-to-treat framework.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.